

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
12 August 2021 (12.08.2021)




(10) International Publication Number
WO 2021/156609 A1

- (51) **International Patent Classification:**
C12N 15/86 (2006.01) *C12N 15/87* (2006.01)
- (21) **International Application Number:**
PCT/GB2021/050235
- (22) **International Filing Date:**
03 February 2021 (03.02.2021)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
- | | | |
|-----------|-------------------------------|----|
| 2001486.6 | 04 February 2020 (04.02.2020) | GB |
| 2009241.7 | 17 June 2020 (17.06.2020) | GB |
| 2010835.3 | 14 July 2020 (14.07.2020) | GB |
| 2011437.7 | 23 July 2020 (23.07.2020) | GB |
- (71) **Applicants:** **OXFORD GENETICS LIMITED** [GB/GB]; Medawar Centre, Robert Robinson Avenue, Oxford Oxfordshire OX4 4HG (GB). **OXFORD UNIVERSITY IN-**
- NOVATION LIMITED** [GB/GB]; Buxton Court, 3 West Way, Oxford OX2 0JB (GB).
- (72) **Inventors:** **CAWOOD, Ryan**; c/o Oxford Genetics Limited, Medawar Centre, Robert Robinson Avenue, Oxford Oxfordshire OX4 4HG (GB). **SU, Weiheng**; c/o Oxford Genetics Limited, Medawar Centre, Robert Robinson Avenue, Oxford Oxfordshire OX4 4HG (GB).
- (74) **Agent:** **DEHNS**; St Bride's House, 10 Salisbury Square, London EC4Y 8JD (GB).
- (81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,

(54) **Title:** PROCESS FOR MAKING ADENOASSOCIATED VIRAL VECTORS

Figure 1



(57) **Abstract:** The invention relates to a nucleic acid molecule encoding at least one AAV Rep polypeptide, wherein one or more of the AAV (p5), (p19) and (p40) promoters have been modified to reduce or eliminate expression of one or more of the Rep polypeptides, or the nucleic acid molecule does not encode functional (Rep52) or (Rep40) polypeptides, or the nucleic acid molecule does not encode a functional adenovirus inhibitor sequence. The invention also relates to a process for producing recombinant AAV vectors through the use of a 2-adenovirus system, wherein all of the genes required for AAV replication and packaging (i.e. an AAV rep sequence of the invention, AAV cap and the AAV transfer vector comprising a transgene) may be encoded within two adenoviruses.

[Continued on next page]

SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))